Treating bladder cancer with ARID1A gene changes
Official title: Targeting ARID1A mutated Urothelial Carcinoma
Funded at VA Salt Lake City Healthcare System · NIH-11213965 · Data updated 2026-11-12
This project will develop new treatment approaches for people with bladder cancer whose tumors have changes in the ARID1A gene.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Salt Lake City Healthcare System NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project start | October 1, 2023 |
| Project end | September 30, 2027 |
| Funding year | 2026 |
| NIH project number | 5I01BX005765-03 |
| Project ID | NIH-11213965 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be adults with bladder (urothelial) cancer whose tumor testing shows an ARID1A mutation, likely able to receive care through the Salt Lake City VA system.
✕Less likely to help
People whose tumors do not have ARID1A mutations or who have non-bladder cancers are unlikely to benefit from these specific approaches.
What this research studies
Researchers are focusing on bladder cancers that carry mutations in the ARID1A gene, a change linked to recurrence and resistance to therapy. They will study tumor samples from Veterans alongside laboratory models to learn how ARID1A loss helps cancer cells survive and resist treatment. The team will look for weaknesses created by ARID1A mutations and test drugs or drug combinations that exploit those weaknesses in preclinical experiments. Promising approaches may be advanced toward testing in patients at the VA medical center.
Why it matters
Potential benefit: If successful, this work could lead to targeted therapies that overcome treatment resistance in ARID1A-mutant bladder cancer.
How similar studies have gone: Some preclinical work in other cancers suggests ARID1A-related vulnerabilities can be targeted, but there are currently no approved therapies specific to ARID1A-mutant tumors, so this approach is partly novel.
Where this research is happening
-
VA Salt Lake City Healthcare System
Salt Lake City, United States Active
Researchers
- Principal investigator: Gupta, Sumati — VA Salt Lake City Healthcare System
- Study coordinator: Gupta, Sumati
Related research
Other NIH-funded projects on the same topics.
-
Understanding bladder cancer biology to find new biomarkers and therapies
A study at Tuskegee University will look at the molecules inside high-grade bladder cancer to discover new markers and potential treatment targets.
-
Improved 3D guidance for kidney-sparing endoscopic UTUC treatment
A Vanderbilt team is testing a new 3D-guided approach to precisely locate and treat upper tract urothelial cancer during kidney-sparing endoscopic procedures.
-
Immune cells in bladder cancer: predicting who benefits from stronger pre-surgery therapy
This grant aims to find immune clues in muscle-invasive bladder cancer to identify which patients will best respond to intensified pre-surgery treatment.
-
Synergistic immune boost for bladder cancer with EphrinB2 blocker and PD-1 therapy
A phase II trial tests whether a new EphrinB2 blocker (sEphB4-HSA) plus pembrolizumab can help patients with muscle-invasive bladder cancer who have EphrinB2 and low Nectin4 to fight their cancer.
-
HER2 PET scans to find HER2 differences and predict response to HER2-targeted therapy in bladder cancer
This project uses a PET scan that lights up HER2 to help show which people with metastatic bladder (urothelial) cancer might benefit from HER2-targeted antibody-drug conjugates.
-
IL-12 bladder immune therapy for dogs with invasive bladder cancer
This project gives a sticky IL-12 immune medicine directly into the bladder of pet dogs with invasive bladder cancer to shrink tumors and stimulate immune responses.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.